Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Jiangsu Hengrui Medicine launches Hong Kong IPO to raise ~$1.3B. Wuxi Biologics is selling its drug product plant in Germany to Terumo for €150M.</li>
<li>Chugai Pharmaceutical got conditional approval in Japan for gene therapy product, Elevidys for Duchenne muscular dystrophy. GC Biopharma dosed first patient in Fabry disease drug trial in Korea.</li>
<li>Mayne Pharma was hit hard as an ‘untitled letter’ from the FDA related to certain promotional claims used in a speaker presentation for oral contraceptive Nextstellis, was made public.  </li>
</ul>


Jiangsu Hengrui Medicine launches Hong Kong IPO to raise ~$1.3B. Wuxi Biologics is selling its drug product plant in Germany to Terumo for €150M.
Chugai Pharmaceutical got conditional approval in Japan for gene therapy product, Elevidys for Duchenne muscular dystrophy. GC Biopharma dosed first patient in Fabry disease drug trial in Korea.
Mayne Pharma was hit hard as an ‘untitled letter’ from the FDA related to certain promotional claims used in a speaker presentation for oral contraceptive Nextstellis, was made public.  


APAC Healthcare Weekly (May 18)-Hengrui Medicine, Wuxi Biologics, Chugai, GC Biopharma, Mayne Pharma

Japanese Equity Specialist, Ortus Advisors

Andrew Jackson

Japanese Equity Specialist

Ortus Advisors

<ul>
<li>Positive US-China talks and the de-escalation of tariffs signal a major softening by both sides.</li>
<li>Expect momentum favourites to continue climbing as risk-on greenlights CTA factor buying.</li>
<li>US Pharma rebounded with Trump executive order seen as toothless and vague.</li>
</ul>


Positive US-China talks and the de-escalation of tariffs signal a major softening by both sides.
Expect momentum favourites to continue climbing as risk-on greenlights CTA factor buying.
US Pharma rebounded with Trump executive order seen as toothless and vague.


Japan Morning Connection: Japan Tech and SPE to Continue Higher with Nasdaq100 Back in a Bull Mkt

<ul>
<li>Mixed bag for tech earnings over the Japan long w/e with Lattice, Palantir and On Semi down, Lumentum and Coreweave up.</li>
<li>SMCI cutting guidance a mere 1-week after releasing prem numbers threatens to erode confidence in management.</li>
<li>Pharma will be under pressure after the FDA's picks a perceived vaccine hawk for its Center for Biologics and Research and Trump hints at price pressures.</li>
</ul>


Mixed bag for tech earnings over the Japan long w/e with Lattice, Palantir and On Semi down, Lumentum and Coreweave up.
SMCI cutting guidance a mere 1-week after releasing prem numbers threatens to erode confidence in management.
Pharma will be under pressure after the FDA's picks a perceived vaccine hawk for its Center for Biologics and Research and Trump hints at price pressures.


Japan Morning Connection: Indian-Pakistan Tensions Adding to Geopolitical Concern

Japan Specialist

Mark Chadwick

<ul>
<li>The stock market ended on a strong note, with both the Nikkei 225 (+3.4%) and the  Topix (+3.7%) indices posting substantial weekly gains amid ongoing U.S.-Japan trade negotiations</li>
<li>Japanese Economy Minister Ryosei Akazawa's meeting with President Trump on Thursday proved pivotal, with Trump reportedly identifying a deal with Japan as a "top priority."</li>
<li>Auto stocks posted impressive gains Tuesday after reports that Trump was considering pausing his 25% levies on auto imports, with Mazda (+8%) leading the sector for the week.</li>
</ul>


The stock market ended on a strong note, with both the Nikkei 225 (+3.4%) and the  Topix (+3.7%) indices posting substantial weekly gains amid ongoing U.S.-Japan trade negotiations
Japanese Economy Minister Ryosei Akazawa's meeting with President Trump on Thursday proved pivotal, with Trump reportedly identifying a deal with Japan as a "top priority."
Auto stocks posted impressive gains Tuesday after reports that Trump was considering pausing his 25% levies on auto imports, with Mazda (+8%) leading the sector for the week.


Japan Strategy Weekly | Stocks Rally as Trade Tensions Ease and Hopes Rise for Bilateral Deal

<ul>
<li>FDA has confirmed the primary endpoints for Neuren Pharmaceuticals’ planned Phase 3 pivotal clinical trial of NNZ-2591 in Phelan-McDermid syndrome. Eisai has ultimately received its long-waited European approval for Leqembi.</li>
<li>Chugai Pharmaceutical’s outlicensed oral GLP-1 drug candidate orforglipron has shown positive topline Phase 3 results. Telix announced preliminary results from the Phase 2 study of TLX101 in recurrent high-grade glioma.</li>
<li>Biocon secured market entry date for Yesafili, an interchangeable biosimilar to Eylea in the U.S. FDA has issued Form 483 with 11 observations for Aurobindo Pharma’s North Carolina inhaler plant.</li>
</ul>


FDA has confirmed the primary endpoints for Neuren Pharmaceuticals’ planned Phase 3 pivotal clinical trial of NNZ-2591 in Phelan-McDermid syndrome. Eisai has ultimately received its long-waited European approval for Leqembi.
Chugai Pharmaceutical’s outlicensed oral GLP-1 drug candidate orforglipron has shown positive topline Phase 3 results. Telix announced preliminary results from the Phase 2 study of TLX101 in recurrent high-grade glioma.
Biocon secured market entry date for Yesafili, an interchangeable biosimilar to Eylea in the U.S. FDA has issued Form 483 with 11 observations for Aurobindo Pharma’s North Carolina inhaler plant.


APAC Healthcare Weekly (April 20)- Neuren, Chugai, Eisai, Telix, Biocon, Aurobindo Pharma

Japan

Chugai Pharmaceutical Company Ltd., manufactures and sells pharmaceuticals in the domestic and international markets through its subsidiaries. The Company develops drugs in the fields of cancer, infectious diseases, bone, blood, and circulatory systems. Chugai Pharmaceutical also conducts research studies on drugs with private and public medical research institutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chugai Pharmaceutical (4519 JP)

APAC Healthcare Weekly (May 18)-Hengrui Medicine, Wuxi Biologics, Chugai, GC Biopharma, Mayne Pharma

Jiangsu Hengrui launches HK IPO. Wuxi Biologics to sell Germany plant. Chugai got Japan approval for gene therapy. Mayne Pharma was hit as FDA...

Tina Banerjee

Japan Morning Connection: Japan Tech and SPE to Continue Higher with Nasdaq100 Back in a Bull Mkt

US-China trade tensions ease as tariffs are de-escalated, resulting in risk-on buying across sectors. Should see improved sentiment for Japan...

Andrew Jackson

Japan Morning Connection: Indian-Pakistan Tensions Adding to Geopolitical Concern

Tech earnings in Japan were mixed over the long weekend. Pharma faces pressure from FDA pick and potential price pressures. China talk...

Andrew Jackson

Japan Strategy Weekly | Stocks Rally as Trade Tensions Ease and Hopes Rise for Bilateral Deal

Stock market in Japan surges as U.S.-Japan trade talks progress, with auto stocks seeing significant gains amid potential tariff pause.

Mark Chadwick

APAC Healthcare Weekly (April 20)- Neuren, Chugai, Eisai, Telix, Biocon, Aurobindo Pharma

Neuren is a step closer to P3 trial in PMS. Chugai’s oral GLP-1 drug candidate shows promise in P3 trial. Eisai got Leqembi approval in EU. Biocon...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

APAC Healthcare Weekly (May 18)-Hengrui Medicine, Wuxi Biologics, Chugai, GC Biopharma, Mayne Pharma

Jiangsu Hengrui launches HK IPO. Wuxi Biologics to sell Germany plant. Chugai got Japan approval for gene therapy. Mayne Pharma was hit as FDA...

Tina Banerjee

Japan Morning Connection: Japan Tech and SPE to Continue Higher with Nasdaq100 Back in a Bull Mkt

​US-China trade tensions ease as tariffs are de-escalated, resulting in risk-on buying across sectors. Should see improved sentiment for Japan...

Andrew Jackson

Japan Morning Connection: Indian-Pakistan Tensions Adding to Geopolitical Concern

​Tech earnings in Japan were mixed over the long weekend. Pharma faces pressure from FDA pick and potential price pressures. China talk...

Andrew Jackson

Japan Strategy Weekly | Stocks Rally as Trade Tensions Ease and Hopes Rise for Bilateral Deal

​Stock market in Japan surges as U.S.-Japan trade talks progress, with auto stocks seeing significant gains amid potential tariff pause.

Mark Chadwick

APAC Healthcare Weekly (April 20)- Neuren, Chugai, Eisai, Telix, Biocon, Aurobindo Pharma

Neuren is a step closer to P3 trial in PMS. Chugai’s oral GLP-1 drug candidate shows promise in P3 trial. Eisai got Leqembi approval in EU. Biocon...

Tina Banerjee

US-China trade tensions ease as tariffs are de-escalated, resulting in risk-on buying across sectors. Should see improved sentiment for Japan...

Tech earnings in Japan were mixed over the long weekend. Pharma faces pressure from FDA pick and potential price pressures. China talk...

Stock market in Japan surges as U.S.-Japan trade talks progress, with auto stocks seeing significant gains amid potential tariff pause.